Mina Mohammadi, Mohaddeseh Sadat Mousavi, Shohreh Mohebbi, Mohammad Reza Eskandari, Narges Poursina
{"title":"Hydrogen-bonded poly(vinyl alcohol)/tannic acid/quercetin hydrogels for localized controlled drug delivery.","authors":"Mina Mohammadi, Mohaddeseh Sadat Mousavi, Shohreh Mohebbi, Mohammad Reza Eskandari, Narges Poursina","doi":"10.1080/10837450.2026.2734062","DOIUrl":"10.1080/10837450.2026.2734062","url":null,"abstract":"<p><p>Localized drug delivery systems provide an effective approach for achieving sustained drug release and prolonged drug retention at the target site while minimizing systemic exposure. In this study, physically crosslinked poly(vinyl alcohol)/tannic acid/quercetin (PVA/TA/Que) (PTQ) hydrogels were developed through hydrogen-bond-mediated self-assembly without chemical crosslinkers. The effect of TA concentration on hydrogel formation, structural properties, thermal stability, swelling, degradation, and release behavior was systematically investigated. Increasing TA concentration accelerated gelation, increased gel content, and produced denser hydrogel networks with lower porosity, reduced water uptake, slower degradation, and improved thermal stability. FT-IR and XRD analysis confirmed hydrogen-bond interactions between PVA and TA and reduced polymer crystallinity. PT50 exhibited the most favorable physicochemical properties and was selected for further evaluation. TA encapsulation efficiency exceeded 93%. <i>In vitro</i> studies demonstrated sustained and pH-responsive TA release, with only 27.39 ± 1.14% released over 312 h at pH 7.4, while Que showed a faster release profile. Hemocompatibility assays revealed hemolysis values below 2%, and hematological, biochemical, and histopathological analysis following subcutaneous implantation in rats showed no detectable systemic toxicity. Overall, the PTQ hydrogels demonstrated favorable physicochemical properties, controlled release behavior, excellent hemocompatibility, and good <i>in vivo</i> biosafety, indicating their potential for localized delivery of bioactive agents.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1368-1382"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Investigating the effect of leucine and dipalmitoylphosphatidylcholine on aerosolization properties of high-dose dry powder inhaler formulations of itraconazole nanoparticles.","authors":"Peyman Khoshhal, Mohammadreza Rouini, Kambiz Gilani","doi":"10.1080/10837450.2026.2746980","DOIUrl":"10.1080/10837450.2026.2746980","url":null,"abstract":"<p><p>This study aims to develop a high-dose dry powder inhaler (DPI) formulation of itraconazole (ITZ) nanoparticles with leucine and/or dipalmitoylphosphatidylcholine (DPPC) as excipients to increase drug solubility and aerosolization performance. To do this, we co-spray-dried leucine and DPPC with an optimized ITZ nanosuspension and measured the physical properties, dissolution and aerosolization characteristics of the formulations. Among the formulations, those containing 50% (w/w<sub>ITZ</sub>) leucine (N3) or 30% (w/w<sub>ITZ</sub>) leucine with 20% (w/w<sub>ITZ</sub>) DPPC (N5), which had the highest FPF (68.88 ± 1.90% for N3 and 78.81 ± 1.17% for N5) and dissolved percentage of the drug (cumulative release percentage in 180 min, 69.10 ± 1.46% for N3 and 94.34 ± 1.30% for N5), were selected for <i>in vivo</i> pharmacokinetic studies and insufflated intratracheally to rats. An ITZ suspension was administered as a control by gavage. Among the selected formulations, N3 produced the highest AUC in lung tissue, approximately two-fold higher than N5. Furthermore, the AUC<sub>Lung</sub>-to-AUC<sub>Plasma</sub> ratio for N3 was approximately 24-fold and 800-fold higher than those of N5 and the oral formulations, respectively, indicating enhanced pulmonary retention and potentially reduced systemic exposure. Overall, N3 represents a promising high-dose DPI formulation for further preclinical development of inhaled ITZ.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1514-1531"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mervat Shafik Ibrahim, Nihal Mohamed Elmahdy Elsayyad, Shereen H Noshi
{"title":"Development and optimisation using D-optimal design of dual-functionalized hyaluronic acid-chitosan-coated mesoporous silica nanoparticles for repurposed propranolol delivery in breast cancer: a proof-of-concept study.","authors":"Mervat Shafik Ibrahim, Nihal Mohamed Elmahdy Elsayyad, Shereen H Noshi","doi":"10.1080/10837450.2026.2738747","DOIUrl":"10.1080/10837450.2026.2738747","url":null,"abstract":"<p><p>Drug repurposing combined with nanocarrier systems can accelerate cancer therapy development while reducing the time and cost of conventional drug discovery. We developed and optimised hyaluronic acid (HA)-chitosan (CH)-coated mesoporous silica nanoparticles (HA-CH-Prop-MSNPs) for delivery of the repurposed β-blocker propranolol. A two-stage D-optimal design optimised propranolol loading, then CH and HA coating, using particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency (EE). The formulation (0.2% low-molecular-weight CH, 0.07% HA, 2 mg/mL propranolol, 10 mg/mL mesoporous silica nanoparticles) exhibited a particle size of 200.5 nm, PDI of 0.495, zeta potential of -25.7 mV, and EE of 91.2%. HA-CH coating provided controlled release and shifted the mechanism from near-Fickian diffusion toward an increasing contribution from polymer relaxation-controlled transport. Propranolol release was significantly higher at tumour-mimicking pH 5.5 than at physiological pH 7.4 across all formulations. Compared with free propranolol, HA-CH-Prop-MSNPs reduced the IC<sub>50</sub> against MCF-7 breast cancer cells 2.8-fold while maintaining negligible carrier cytotoxicity. Under accelerated storage conditions (40 °C/75% RH), the formulation remained stable for six months, with less than a 2% reduction in EE. These findings provide proof of concept that HA-CH-coated mesoporous silica nanoparticles enhance the <i>in vitro</i> anticancer activity of repurposed propranolol through encapsulation and controlled release, laying the foundation for future investigation of HA-mediated cellular targeting.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1405-1424"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149030962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Siyabonga Melamane, Omobolanle A Omoteso, Sandile M Khamanga, Roderick B Walker
{"title":"The design and optimization of a chitosan-based lamotrigine-loaded intranasal mucoadhesive nanomicelle solution using response surface methodology and artificial neural networks.","authors":"Siyabonga Melamane, Omobolanle A Omoteso, Sandile M Khamanga, Roderick B Walker","doi":"10.1080/10837450.2026.2726934","DOIUrl":"10.1080/10837450.2026.2726934","url":null,"abstract":"<p><p>The study aimed to develop and optimize chitosan-based mucoadhesive nanomicelles for intranasal delivery of lamotrigine (LTG), to enhance epilepsy treatment, bypass the blood-brain barrier, and potentially improve brain targeting. LTG-loaded nanomicelles were prepared using thin-film hydration and optimized using a central composite design, response surface methodology, and artificial neural networks. The formulation included D-ɑ-tocopheryl polyethylene glycol succinate, Poloxamer 407, chitosan, and glycerol. Critical quality attributes assessed were micelle size (MS), polydispersity index (PDI), Zeta potential (ZP), pH, LTG content, transmittance, <i>in vitro</i> mucoadhesion, LTG release, and 28-day stability. The MS, PDI, ZP, pH, and LTG content of the optimized mucoadhesive nanomicelles was 31.28 ± 0.34 nm, 0.487 ± 0.00, +31.37 ± 1.97 mV, 4.61 ± 0.01, and 2.89 ± 0.01 mg/mL, respectively. The transmittance was 98.50 ± 0.10%, and significant <i>in vitro</i> mucoadhesion, with reduced migration, was observed for mucin-containing gels. LTG release (96.94% at 6 h) followed the Higuchi diffusion model, with sufficient LTG released at 40 min to potentially reach the minimum effective concentration, based on <i>in vitro</i> release data alone. The formulation remained stable for 28 days at 4 °C and 25 °C. Chitosan-based mucoadhesive nanomicelles are a promising intranasal delivery system for LTG, with the potential for brain targeting, controlled LTG release, and improved epilepsy management.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1232-1254"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148851212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sustained intravitreal delivery of triamcinolone acetonide via in situ forming lipid liquid crystals: in-vitro and in-vivo evaluations.","authors":"Fatemeh Asgharian Rezae, Malihe Karimi, Mojtaba Abrishami, Hossein Kamali, Bizhan Malaekeh-Nikouei","doi":"10.1080/10837450.2026.2726937","DOIUrl":"10.1080/10837450.2026.2726937","url":null,"abstract":"<p><p>Posterior segment disorders remain challenging to manage due to limitations in ocular drug delivery. Although intravitreal triamcinolone acetonide (TA) is effective, it requires repeated administration, highlighting the need for sustained-release systems. This study aimed to develop <i>in situ</i> sustained-release formulations of TA using lipid liquid crystals (LLCs). Formulations were prepared with glyceryldioleate (GDO), phosphatidylcholine (PC), and N-methyl pyrrolidone (NMP) at PC:GDO ratios of 50:50, 40:60, and 60:40. A TA-hydroxypropyl-β-cyclodextrin (HPβCD) complex was also prepared. The formulations were characterized for rheological properties, morphology, degradation, and water uptake. <i>In-vitro</i> release was assessed in phosphate-buffered saline (pH 7.4), while <i>in-vivo</i> pharmacokinetics were evaluated in rabbits, comparing a selected LLC formulation with a TA suspension. The F5 formulation (40:60 PC: GDO) achieved sustained release of 35.4% over one month and exhibited superior stability, with 24.9% less degradation compared to F6, which showed undesirable drug crystallization. The TA-HPβCD complex demonstrated an even slower release (28%). F4 (50:50 PC: GDO) was selected as the optimized formulation, demonstrating the lowest water absorption and degradation with a consistent release profile. <i>In-vivo</i> studies confirmed that LLCs provided more controlled and prolonged release compared with conventional TA suspension. In conclusion, LLC-based TA formulations offer a promising strategy for sustained intravitreal drug delivery, with biodegradability, ease of preparation, and prolonged therapeutic levels.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1280-1310"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148912084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Self-assembled ufasomes of unsaturated fatty acids: mechanisms, characterization, and drug delivery potential.","authors":"Raghavi Bansal, Deepanshi Baloni, Manoj Kumar Mishra","doi":"10.1080/10837450.2026.2713500","DOIUrl":"10.1080/10837450.2026.2713500","url":null,"abstract":"<p><p>Ufasomes-vesicular systems formed from long-chain unsaturated fatty acids such as oleic acid-have re-emerged as cost-effective, biocompatible alternatives to phospholipid liposomes. These bilayered assemblies self-organize at specific pH conditions and efficiently encapsulate both hydrophilic and lipophilic drugs. Their highly fluid membranes, attributed to cis-double-bond-induced structural disorder, enhance interaction with biological barriers, particularly the stratum corneum, making them valuable for topical and transdermal delivery. This review outlines the chemistry and self-assembly of ufasomes, followed by a critical appraisal of preparation techniques-including thin-film hydration and reverse-phase evaporation-and their influence on vesicle size, stability and encapsulation efficiency. Advantages such as biocompatibility, biodegradability and pH-responsive release are highlighted alongside limitations including pH-dependent instability and oxidative susceptibility. Key characterization approaches are summarized, and the therapeutic scope of ufasomes is examined, encompassing enhanced dermal delivery of antifungals and antidepressants, targeted cancer therapy, and improved oral bioavailability of nutraceuticals like oleuropein. The review concludes with emerging strategies to overcome current constraints and perspectives on advancing ufasomes toward clinical translation as versatile drug-delivery systems.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1137-1171"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148670593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Light source-dependent photooxidation of therapeutic monoclonal antibodies: a comparative study of light-emitting diode (LED) and fluorescent exposure.","authors":"Eva-Maria Baur, Lukas Bollenbach, Torsten Schultz-Fademrecht, Dariush Hinderberger, Michaela Blech, Patrick Garidel","doi":"10.1080/10837450.2026.2725579","DOIUrl":"10.1080/10837450.2026.2725579","url":null,"abstract":"<p><p>Although therapeutic proteins are susceptible to visible light-induced photooxidation, the underlying mechanisms remain unclear because amino acid residues do not directly absorb light above 400 nm. To evaluate the role of light source characteristics, three monoclonal antibodies formulated in water were exposed to spectrally distinct fluorescent and light-emitting diode (LED) sources, eliminating excipient-related effects. Following exposure to visible light (400-800 nm), degradation was assessed by size-exclusion, Protein A, and ion-exchange chromatography, together with mass spectrometry. The LED spectrum displayed a pronounced emission at 451 nm and a broad band between 480 and 800 nm, whereas the fluorescent lamp exhibited prominent emissions at 436, 545, and 612 nm, with additional blue-light contributions overlapping antibody absorption. Both light sources induced dose- and antibody-dependent photodegradation, characterized by increased high molecular weight species, Fc-oxidation, acidic and basic charge variants, and methionine and tryptophan oxidation, without detectable fragmentation. Monomer content decreased by 1-4 %, Fc-oxidized variants increased by 5-20 %, and the ion-exchange main peak decreased by 2-8 %. LED-induced degradation was less pronounced than that induced by fluorescent light, reflecting reduced short-wavelength emission. These findings support photosensitizer-mediated oxidation at 400-450 nm and highlight the importance of controlling light exposure during bioprocessing.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1197-1216"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148851194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zhongjin Huang, Guoxin Du, Minghu Chen, Zuliang Yao, Bo Liang, Fei Ren
{"title":"Development and preclinical evaluation of a copper-based acidic hydrogel for atopic dermatitis.","authors":"Zhongjin Huang, Guoxin Du, Minghu Chen, Zuliang Yao, Bo Liang, Fei Ren","doi":"10.1080/10837450.2026.2708938","DOIUrl":"10.1080/10837450.2026.2708938","url":null,"abstract":"<p><p>Atopic dermatitis (AD) features impaired skin barrier, elevated cutaneous pH, and <i>Staphylococcus aureus</i> overcolonization. Restoring acidic skin pH while suppressing microbial overgrowth represents a promising non-steroidal strategy. To develop a copper-based acidic hydrogel and evaluate its properties, antimicrobial activity, efficacy, and safety. A hydrogel with 0.115% copper ions was prepared from basic copper carbonate, acetic acid (6% w/w), and xanthan gum, formulated at a final pH of ∼3.2, and characterized by rheology and stability testing. Antimicrobial activity was evaluated by a quantitative carrier test against <i>S. aureus</i>, <i>E. coli</i>, and <i>C. albicans</i>. Efficacy was assessed in DNFB-induced AD-like BALB/c mice. Dermal safety was examined in a 14-day study in rabbits. The hydrogel showed gel-like behavior (G' > G″) with 94.6% structural recovery and remained stable over 23 months. It achieved >98% killing of all pathogens within 5 min and >99.6% within 10 min. In mice, treatment dose-dependently reduced ear swelling and dermatitis scores, attenuated epidermal hyperplasia, and decreased mast cell infiltration. In rabbits, only mild, reversible local irritation occurred, without systemic toxicity. This copper-based acidic hydrogel exhibits potent broad-spectrum antimicrobial activity, ameliorates AD-like lesions, and shows a favorable short-term dermal safety profile, supporting further development as a non-steroidal topical option for AD.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1126-1136"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148685508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
George Patrick Devon, Dzava Prawinsyah Fairus Ismail, Jenio Lagut, Iyan Sopyan
{"title":"Solid modification strategies for active pharmaceutical ingredients (APIs): a systematic review on approaches, improvements, and limitations.","authors":"George Patrick Devon, Dzava Prawinsyah Fairus Ismail, Jenio Lagut, Iyan Sopyan","doi":"10.1080/10837450.2026.2725578","DOIUrl":"10.1080/10837450.2026.2725578","url":null,"abstract":"<p><p>Poor aqueous solubility remains a major barrier in drug development, affecting approximately 40% of marketed drugs, up to 75% of drugs under development, and nearly 90% of new chemical entities. To overcome this limitation, solid modification of active pharmaceutical ingredients (APIs) emerged as a strategy to enhance drug physicochemical properties, particularly for Biopharmaceutics Classification System (BCS) II and IV drugs. This review systematically analyzes recent advancements in solid modification techniques, including salt formation, cocrystallization, polymorphs, solvate and hydrate forms, amorphous and co-amorphous systems, inclusion complexes, and nanocrystallization. A systematic literature search spanning 2020-2025 was conducted using PubMed and ScienceDirect databases, focusing on studies that improve the physicochemical properties of the APIs. By categorizing APIs, matrices, and methods of each study, this review shows the most frequently used techniques and their matrices, advantages, and limitations of each modification, providing insights for optimizing drug performance and future research in pharmaceutical development. Among the various approaches reviewed, cocrystals, amorphous systems, nanocrystals, and inclusion complexes emerged as the most frequently used techniques. Amorphous systems and inclusion complexes offer the highest median solubility enhancements by maximizing kinetic supersaturation or equilibrium solubility, respectively, while nanocrystals efficiently improve equilibrium solubility <i>via</i> particle size reduction, and cocrystals provide reliable, moderate gains with superior long-term thermodynamic stability.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1172-1196"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149002222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mohammad Hassan Shahriari, Hossein Salmani, Mohammad Adel Ghiass, Nader Kamali, Atefeh Malek-Khatabi, Hussein Abdelamir Mohammad, Saba Saei, Mohammad Akrami
{"title":"Innovative hybrid microneedle patch for co-delivery of varenicline and melatonin: development, characterization, and potential for smoking cessation.","authors":"Mohammad Hassan Shahriari, Hossein Salmani, Mohammad Adel Ghiass, Nader Kamali, Atefeh Malek-Khatabi, Hussein Abdelamir Mohammad, Saba Saei, Mohammad Akrami","doi":"10.1080/10837450.2026.2726936","DOIUrl":"10.1080/10837450.2026.2726936","url":null,"abstract":"<p><p>Smoking cessation remains a therapeutic challenge, and limitations associated with conventional oral varenicline therapy may affect patient adherence. This study aimed to develop and characterize a dissolving microneedle patch co-loaded with varenicline and melatonin for transdermal delivery. Microneedle arrays were fabricated using polyvinyl alcohol (PVA) and polyvinylpyrrolidone (PVP), with Tween-80 incorporated to enhance the solubility of varenicline. The fabricated microneedles were evaluated for their mechanical and surface properties using nanoindentation, scratch testing, and atomic force microscopy. In vitro drug release and transdermal permeation studies were performed, while fluorescence imaging and histological analysis were used to assess microneedle insertion and skin integrity. The microneedles exhibited adequate hardness and flexibility, together with a uniform surface morphology, supporting effective penetration into the skin. Following 48 h of application, cumulative transdermal permeation of varenicline and melatonin reached 34.3% and 41.6%, respectively. The co-loaded microneedle formulation provided sustained release of both drugs over the study period. Histological evaluation confirmed the formation of discrete microchannels following microneedle insertion without significant disruption of the surrounding tissue. Overall, the findings demonstrate the feasibility of a varenicline-melatonin-loaded microneedle patch as a transdermal drug-delivery system for smoking cessation. Further investigation, including comparison with established commercial therapies and ex vivo dissolution and permeation studies, is warranted to establish its translational potential.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1255-1279"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}